25 XP   0   0   10

AlzeCure Pharma
Buy, Hold or Sell?

Let's analyse AlzeCure Pharma together

PenkeI guess you are interested in AlzeCure Pharma. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of AlzeCure Pharma. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about AlzeCure Pharma

I send you an email if I find something interesting about AlzeCure Pharma.

Quick analysis of AlzeCure Pharma (30 sec.)










What can you expect buying and holding a share of AlzeCure Pharma? (30 sec.)

How much money do you get?

How much money do you get?
kr0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
kr0.66
Expected worth in 1 year
kr0.62
How sure are you?
21.7%

+ What do you gain per year?

Total Gains per Share
kr-0.03
Return On Investment
-0.8%

For what price can you sell your share?

Current Price per Share
kr4.12
Expected price per share
kr3.13 - kr4.52
How sure are you?
50%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1. Valuation of AlzeCure Pharma (5 min.)




Live pricePrice per Share (EOD)

kr4.12

Intrinsic Value Per Share

kr-0.13 - kr0.30

Total Value Per Share

kr0.53 - kr0.96

2. Growth of AlzeCure Pharma (5 min.)




Is AlzeCure Pharma growing?

Current yearPrevious yearGrowGrow %
How rich?$3.7m$4.3m-$196.4k-4.7%

How much money is AlzeCure Pharma making?

Current yearPrevious yearGrowGrow %
Making money-$936.2k-$1.6m$719.7k76.9%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of AlzeCure Pharma (5 min.)




4. Comparing to competitors in the Drug Manufacturers-Specialty & Generic industry (5 min.)




  Industry Rankings (Drug Manufacturers-Specialty & Generic)  


Richest
#536 / 640

Most Revenue
#629 / 640

Most Profit
#390 / 640

Most Efficient
#351 / 640
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

What can you expect buying and holding a share of AlzeCure Pharma? (5 min.)

Welcome investor! AlzeCure Pharma's management wants to use your money to grow the business. In return you get a share of AlzeCure Pharma.

What can you expect buying and holding a share of AlzeCure Pharma?

First you should know what it really means to hold a share of AlzeCure Pharma. And how you can make/lose money.

Speculation

The Price per Share of AlzeCure Pharma is kr4.12. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of AlzeCure Pharma.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in AlzeCure Pharma, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is kr0.66. Based on the TTM, the Book Value Change Per Share is kr-0.01 per quarter. Based on the YOY, the Book Value Change Per Share is kr-0.12 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is kr0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of AlzeCure Pharma.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 kr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Share
Usd Eps-0.01-0.4%-0.02-0.4%-0.03-0.6%-0.02-0.5%-0.02-0.5%
Usd Book Value Change Per Share-0.01-0.4%0.000.0%-0.01-0.3%0.000.0%0.000.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.01-0.4%0.000.0%-0.01-0.3%0.000.0%0.000.1%
Usd Price Per Share0.47-0.45-0.44-0.51-0.44-
Price to Earnings Ratio-8.04--7.41--4.29--6.03--5.24-
Price-to-Total Gains Ratio-32.84--21.49--11.42--20.15--20.15-
Price to Book Ratio7.97-7.24-6.63-4.50-3.92-
Price-to-Total Gains Ratio-32.84--21.49--11.42--20.15--20.15-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.372448
Number of shares2684
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (2684 shares)-2.05-2.15
Gains per Year (2684 shares)-8.21-8.60
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-8-180-9-19
20-16-260-17-28
30-25-340-26-37
40-33-420-34-46
50-41-500-43-55
60-49-580-52-64
70-57-660-60-73
80-66-740-69-82
90-74-820-77-91
100-82-900-86-100

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.023.00.00.0%0.023.00.00.0%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%4.016.00.020.0%5.016.02.021.7%5.016.02.021.7%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.023.00.0%0.00.023.00.0%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%4.016.00.020.0%5.016.02.021.7%5.016.02.021.7%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

Fundamentals of AlzeCure Pharma

About AlzeCure Pharma

AlzeCure Pharma AB (publ), a pharmaceutical company, develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is developing drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its pipeline products include ACD856, which is in phase I clinical trial to treat Alzheimer's disease, sleep disorders, traumatic brain injuries, and Parkinson's disease; ACD857, ACD679, and ACD680 that are in preclinical trial for the treatment of Alzheimer's disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain; and TrkA-NAM for osteoarthritic pain. The company was founded in 2012 and is based in Huddinge, Sweden.

Fundamental data was last updated by Penke on 2023-09-15 17:58:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.1. Profitability of AlzeCure Pharma.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit AlzeCure Pharma earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compare AlzeCure Pharma to the Drug Manufacturers-Specialty & Generic industry mean.
  • A Net Profit Margin of 0.0% means that kr0.00 for each kr1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of AlzeCure Pharma:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.3%-2.3%
TTM-1.9%-1.9%
YOY-2.9%-2.9%
5Y-1.4%-1.4%
10Y-2.2%-2.2%
1.1.2. Return on Assets

Shows how efficient AlzeCure Pharma is using its assets to generate profit.

  • Above 5% is considered healthy but always compare AlzeCure Pharma to the Drug Manufacturers-Specialty & Generic industry mean.
  • -21.2% Return on Assets means that AlzeCure Pharma generated kr-0.21 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of AlzeCure Pharma:

  • The MRQ is -21.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -20.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-21.2%TTM-20.0%-1.3%
TTM-20.0%YOY-32.3%+12.4%
TTM-20.0%5Y-17.0%-3.0%
5Y-17.0%10Y-16.6%-0.4%
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ-21.2%0.2%-21.4%
TTM-20.0%0.1%-20.1%
YOY-32.3%0.4%-32.7%
5Y-17.0%0.3%-17.3%
10Y-16.6%0.5%-17.1%
1.1.3. Return on Equity

Shows how efficient AlzeCure Pharma is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare AlzeCure Pharma to the Drug Manufacturers-Specialty & Generic industry mean.
  • -24.8% Return on Equity means AlzeCure Pharma generated kr-0.25 for each kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of AlzeCure Pharma:

  • The MRQ is -24.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -23.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-24.8%TTM-23.9%-0.9%
TTM-23.9%YOY-42.2%+18.3%
TTM-23.9%5Y-20.3%-3.6%
5Y-20.3%10Y-19.6%-0.7%
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ-24.8%1.0%-25.8%
TTM-23.9%0.7%-24.6%
YOY-42.2%0.9%-43.1%
5Y-20.3%0.4%-20.7%
10Y-19.6%0.9%-20.5%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.2. Operating Efficiency of AlzeCure Pharma.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient AlzeCure Pharma is operating .

  • Measures how much profit AlzeCure Pharma makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare AlzeCure Pharma to the Drug Manufacturers-Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated kr0.00  for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of AlzeCure Pharma:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.9%-2.9%
TTM-1.8%-1.8%
YOY-5.3%-5.3%
5Y-4.7%-4.7%
10Y-3.2%-3.2%
1.2.2. Operating Ratio

Measures how efficient AlzeCure Pharma is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers-Specialty & Generic industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are kr0.00 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of AlzeCure Pharma:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.378-1.378
TTM-1.393-1.393
YOY-1.383-1.383
5Y-1.416-1.416
10Y-1.188-1.188
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.3. Liquidity of AlzeCure Pharma.

1.3. Liquidity
1.3.1. Current Ratio

Measures if AlzeCure Pharma is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers-Specialty & Generic industry mean).
  • A Current Ratio of 6.85 means the company has kr6.85 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of AlzeCure Pharma:

  • The MRQ is 6.851. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.562. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.851TTM5.562+1.290
TTM5.562YOY4.615+0.947
TTM5.5625Y19.420-13.859
5Y19.42010Y17.471+1.949
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ6.8511.835+5.016
TTM5.5621.886+3.676
YOY4.6152.122+2.493
5Y19.4202.351+17.069
10Y17.4712.086+15.385
1.3.2. Quick Ratio

Measures if AlzeCure Pharma is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare AlzeCure Pharma to the Drug Manufacturers-Specialty & Generic industry mean.
  • A Quick Ratio of 6.52 means the company can pay off kr6.52 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of AlzeCure Pharma:

  • The MRQ is 6.523. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 5.279. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ6.523TTM5.279+1.244
TTM5.279YOY4.501+0.778
TTM5.2795Y19.147-13.867
5Y19.14710Y17.215+1.932
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ6.5230.758+5.765
TTM5.2790.782+4.497
YOY4.5011.048+3.453
5Y19.1471.084+18.063
10Y17.2151.089+16.126
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.4. Solvency of AlzeCure Pharma.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of AlzeCure Pharma assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare AlzeCure Pharma to Drug Manufacturers-Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.14 means that AlzeCure Pharma assets are financed with 14.4% credit (debt) and the remaining percentage (100% - 14.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of AlzeCure Pharma:

  • The MRQ is 0.144. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.156. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.144TTM0.156-0.012
TTM0.156YOY0.218-0.062
TTM0.1565Y0.106+0.050
5Y0.10610Y0.102+0.004
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1440.428-0.284
TTM0.1560.430-0.274
YOY0.2180.393-0.175
5Y0.1060.401-0.295
10Y0.1020.402-0.300
1.4.2. Debt to Equity Ratio

Measures if AlzeCure Pharma is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare AlzeCure Pharma to the Drug Manufacturers-Specialty & Generic industry mean.
  • A Debt to Equity ratio of 16.8% means that company has kr0.17 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of AlzeCure Pharma:

  • The MRQ is 0.168. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.187. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.168TTM0.187-0.019
TTM0.187YOY0.282-0.094
TTM0.1875Y0.127+0.060
5Y0.12710Y0.121+0.006
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1680.682-0.514
TTM0.1870.693-0.506
YOY0.2820.617-0.335
5Y0.1270.689-0.562
10Y0.1210.712-0.591
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

2. Market Valuation of AlzeCure Pharma

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every kr1 in earnings AlzeCure Pharma generates.

  • Above 15 is considered overpriced but always compare AlzeCure Pharma to the Drug Manufacturers-Specialty & Generic industry mean.
  • A PE ratio of -8.04 means the investor is paying kr-8.04 for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of AlzeCure Pharma:

  • The EOD is -6.318. Based on the earnings, the company is expensive. -2
  • The MRQ is -8.036. Based on the earnings, the company is expensive. -2
  • The TTM is -7.409. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.318MRQ-8.036+1.718
MRQ-8.036TTM-7.409-0.626
TTM-7.409YOY-4.286-3.123
TTM-7.4095Y-6.025-1.384
5Y-6.02510Y-5.239-0.786
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
EOD-6.3185.016-11.334
MRQ-8.0363.693-11.729
TTM-7.4092.965-10.374
YOY-4.2865.146-9.432
5Y-6.0256.616-12.641
10Y-5.23913.646-18.885
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of AlzeCure Pharma:

  • The EOD is -7.244. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -9.213. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.406. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.244MRQ-9.213+1.969
MRQ-9.213TTM-3.406-5.808
TTM-3.406YOY-2.934-0.471
TTM-3.4065Y-4.982+1.576
5Y-4.98210Y-4.332-0.650
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
EOD-7.244-0.400-6.844
MRQ-9.213-0.678-8.535
TTM-3.406-1.296-2.110
YOY-2.934-2.222-0.712
5Y-4.982-1.632-3.350
10Y-4.332-3.189-1.143
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of AlzeCure Pharma is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers-Specialty & Generic industry mean).
  • A PB ratio of 7.97 means the investor is paying kr7.97 for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of AlzeCure Pharma:

  • The EOD is 6.266. Based on the equity, the company is overpriced. -1
  • The MRQ is 7.969. Based on the equity, the company is overpriced. -1
  • The TTM is 7.242. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD6.266MRQ7.969-1.703
MRQ7.969TTM7.242+0.727
TTM7.242YOY6.630+0.613
TTM7.2425Y4.504+2.738
5Y4.50410Y3.917+0.588
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
EOD6.2661.640+4.626
MRQ7.9691.671+6.298
TTM7.2421.655+5.587
YOY6.6302.095+4.535
5Y4.5042.534+1.970
10Y3.9173.327+0.590
2. Total Gains per Share
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

3. Summary

3.1. Key Performance Indicators

The key performance indicators of AlzeCure Pharma compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.160-0.008-95%-0.117-26%-0.009-94%0.029-658%
Book Value Per Share--0.6580.740-11%0.778-15%1.775-63%1.652-60%
Current Ratio--6.8515.562+23%4.615+48%19.420-65%17.471-61%
Debt To Asset Ratio--0.1440.156-8%0.218-34%0.106+36%0.102+42%
Debt To Equity Ratio--0.1680.187-10%0.282-40%0.127+32%0.121+39%
Dividend Per Share----0%-0%-0%-0%
Eps---0.163-0.168+3%-0.295+81%-0.237+45%-0.222+36%
Free Cash Flow Per Share---0.142-0.188+32%-0.283+99%-0.236+66%-0.222+56%
Free Cash Flow To Equity Per Share---0.1350.152-189%0.227-160%0.111-222%0.107-227%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--0.303--------
Intrinsic Value_10Y_min---0.126--------
Intrinsic Value_1Y_max---0.880--------
Intrinsic Value_1Y_min---0.865--------
Intrinsic Value_3Y_max---1.950--------
Intrinsic Value_3Y_min---1.876--------
Intrinsic Value_5Y_max---2.184--------
Intrinsic Value_5Y_min---2.087--------
Market Cap255798440.000-28%328217942.880308420180.480+6%300113036.250+9%349702524.746-6%304089151.953+8%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio6.266-27%7.9697.242+10%6.630+20%4.504+77%3.917+103%
Pe Ratio-6.318+21%-8.036-7.409-8%-4.286-47%-6.025-25%-5.239-35%
Price Per Share4.120-27%5.2404.950+6%4.834+8%5.629-7%4.895+7%
Price To Free Cash Flow Ratio-7.244+21%-9.213-3.406-63%-2.934-68%-4.982-46%-4.332-53%
Price To Total Gains Ratio-25.819+21%-32.837-21.491-35%-11.419-65%-20.145-39%-20.145-39%
Quick Ratio--6.5235.279+24%4.501+45%19.147-66%17.215-62%
Return On Assets---0.212-0.200-6%-0.323+52%-0.170-20%-0.166-22%
Return On Equity---0.248-0.239-4%-0.422+70%-0.203-18%-0.196-21%
Total Gains Per Share---0.160-0.008-95%-0.117-26%-0.009-94%0.029-658%
Usd Book Value--3723124.0004169044.600-11%4365483.800-15%9963797.600-63%9275256.174-60%
Usd Book Value Change Per Share---0.014-0.001-95%-0.011-26%-0.001-94%0.003-658%
Usd Book Value Per Share--0.0590.067-11%0.070-15%0.160-63%0.149-60%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.015-0.015+3%-0.027+81%-0.021+45%-0.020+36%
Usd Free Cash Flow---805102.400-1051103.400+31%-1590746.200+98%-1324970.200+65%-1245877.078+55%
Usd Free Cash Flow Per Share---0.013-0.017+32%-0.026+99%-0.021+66%-0.020+56%
Usd Free Cash Flow To Equity Per Share---0.0120.014-189%0.021-160%0.010-222%0.010-227%
Usd Market Cap23124178.976-28%29670902.03627881184.315+6%27130218.477+9%31613108.237-6%27489659.337+8%
Usd Price Per Share0.372-27%0.4740.447+6%0.437+8%0.509-7%0.442+7%
Usd Profit---923074.400-936250.200+1%-1655992.400+79%-1329860.840+44%-1246879.339+35%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---0.014-0.001-95%-0.011-26%-0.001-94%0.003-658%
 EOD+3 -5MRQTTM+15 -14YOY+17 -125Y+9 -2010Y+11 -18

3.2. Fundamental Score

Let's check the fundamental score of AlzeCure Pharma based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-6.318
Price to Book Ratio (EOD)Between0-16.266
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than16.523
Current Ratio (MRQ)Greater than16.851
Debt to Asset Ratio (MRQ)Less than10.144
Debt to Equity Ratio (MRQ)Less than10.168
Return on Equity (MRQ)Greater than0.15-0.248
Return on Assets (MRQ)Greater than0.05-0.212
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of AlzeCure Pharma based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose3.900
Total0/1 (0.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-06-302022-09-302022-12-312023-03-312023-06-30
Income Tax Expense  -26-49-75-7-82-135-217509292



Latest Balance Sheet

Balance Sheet of 2023-06-30. Currency in SEK. All numbers in thousands.

Summary
Total Assets48,119
Total Liabilities6,934
Total Stockholder Equity41,185
 As reported
Total Liabilities 6,934
Total Stockholder Equity+ 41,185
Total Assets = 48,119

Assets

Total Assets48,119
Total Current Assets47,507
Long-term Assets47,507
Total Current Assets
Cash And Cash Equivalents 45,232
Total Current Assets  (as reported)47,507
Total Current Assets  (calculated)45,232
+/- 2,275
Long-term Assets
Property Plant Equipment 595
Intangible Assets 17
Long-term Assets  (as reported)612
Long-term Assets  (calculated)612
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities6,934
Long-term Liabilities0
Total Stockholder Equity41,185
Total Current Liabilities
Accounts payable 1,972
Other Current Liabilities 4,962
Total Current Liabilities  (as reported)6,934
Total Current Liabilities  (calculated)6,934
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock1,552
Retained Earnings -322,807
Capital Surplus 362,440
Total Stockholder Equity (as reported)41,185
Total Stockholder Equity (calculated)41,185
+/-0
Other
Capital Stock1,552
Cash and Short Term Investments 45,232
Common Stock Shares Outstanding 62,637
Liabilities and Stockholders Equity 48,119
Net Debt -45,232
Net Invested Capital 41,185
Net Working Capital 40,573



Balance Sheet

Currency in SEK. All numbers in thousands.

 Trend2023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-31
> Total Assets 
55,971
0
0
66,969
237,782
225,876
215,418
201,596
186,755
176,406
160,057
138,334
117,827
99,065
82,030
68,299
45,647
75,561
55,303
40,486
70,836
57,974
48,119
48,11957,97470,83640,48655,30375,56145,64768,29982,03099,065117,827138,334160,057176,406186,755201,596215,418225,876237,78266,9690055,971
   > Total Current Assets 
55,705
0
0
66,305
237,161
224,581
214,074
200,051
184,963
174,696
158,185
136,397
115,859
97,221
80,293
66,708
44,201
74,259
54,146
39,474
27,505
57,237
47,507
47,50757,23727,50539,47454,14674,25944,20166,70880,29397,221115,859136,397158,185174,696184,963200,051214,074224,581237,16166,3050055,705
       Cash And Cash Equivalents 
53,952
0
0
65,746
234,549
222,054
210,315
196,842
182,499
172,230
153,325
132,976
112,434
94,163
77,915
62,672
41,741
25,683
51,673
37,169
25,577
53,718
45,232
45,23253,71825,57737,16951,67325,68341,74162,67277,91594,163112,434132,976153,325172,230182,499196,842210,315222,054234,54965,7460053,952
       Net Receivables 
0
0
0
0
0
0
8
8
1,934
1,356
2,824
2,753
2,357
1,589
1,323
1,708
1,539
46,985
1,452
1,333
0
0
0
0001,3331,45246,9851,5391,7081,3231,5892,3572,7532,8241,3561,93488000000
       Other Current Assets 
1,753
0
0
559
2,612
2,527
3,759
3,209
2,464
2,466
4,860
3,421
3,425
3,058
2,378
4,036
2,460
48,576
2,473
2,305
0
0
0
0002,3052,47348,5762,4604,0362,3783,0583,4253,4214,8602,4662,4643,2093,7592,5272,612559001,753
   > Long-term Assets 
266
0
0
664
621
1,295
1,344
1,545
1,792
1,710
1,872
1,937
1,968
1,844
1,737
1,591
1,446
1,302
1,157
1,012
43,331
737
612
61273743,3311,0121,1571,3021,4461,5911,7371,8441,9681,9371,8721,7101,7921,5451,3441,29562166400266
       Property Plant Equipment 
242
0
0
640
597
1,271
1,320
1,521
1,768
1,686
1,848
1,913
1,944
1,820
1,713
1,567
1,422
1,278
1,133
988
852
720
595
5957208529881,1331,2781,4221,5671,7131,8201,9441,9131,8481,6861,7681,5211,3201,27159764000242
       Intangible Assets 
17
0
0
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17171717171717171717171717171717171717170017
       Long-term Assets Other 
7
0
0
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
42,462
0
0
0042,46277777777777777777007
> Total Liabilities 
4,146
0
0
2,543
4,613
4,674
4,394
3,954
4,748
8,183
10,127
9,859
7,072
11,272
9,930
12,706
12,673
13,890
12,378
8,658
10,354
6,998
6,934
6,9346,99810,3548,65812,37813,89012,67312,7069,93011,2727,0729,85910,1278,1834,7483,9544,3944,6744,6132,543004,146
   > Total Current Liabilities 
4,146
0
0
2,543
4,613
4,674
4,394
3,954
4,748
8,183
10,127
9,859
7,072
11,272
9,930
12,706
12,673
13,890
12,378
8,658
10,354
6,998
6,934
6,9346,99810,3548,65812,37813,89012,67312,7069,93011,2727,0729,85910,1278,1834,7483,9544,3944,6744,6132,543004,146
       Accounts payable 
1,332
0
0
1,672
3,646
3,802
3,785
2,707
2,997
6,391
7,636
7,812
3,966
7,232
5,865
7,722
5,971
4,030
4,463
3,117
4,845
1,832
1,972
1,9721,8324,8453,1174,4634,0305,9717,7225,8657,2323,9667,8127,6366,3912,9972,7073,7853,8023,6461,672001,332
       Other Current Liabilities 
2,814
0
0
871
967
872
609
1,247
1,751
1,792
2,491
2,047
3,106
4,040
4,065
4,984
5,168
9,860
7,915
5,541
5,509
5,166
4,962
4,9625,1665,5095,5417,9159,8605,1684,9844,0654,0403,1062,0472,4911,7921,7511,247609872967871002,814
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,030
4,463
3,117
4,845
1,832
0
01,8324,8453,1174,4634,03000000000000000000
> Total Stockholder Equity
51,825
0
0
64,426
233,169
221,202
211,024
197,642
182,007
168,223
149,930
128,475
110,755
87,793
72,100
55,593
32,974
61,671
42,925
31,828
60,482
50,976
41,185
41,18550,97660,48231,82842,92561,67132,97455,59372,10087,793110,755128,475149,930168,223182,007197,642211,024221,202233,16964,4260051,825
   Common Stock
189
0
0
235
944
944
944
944
944
944
944
944
944
944
944
944
944
944
1,268
1,268
1,268
1,552
1,552
1,5521,5521,2681,2681,26894494494494494494494494494494494494494494423500189
   Retained Earnings -322,807-312,596-303,051-292,103-281,006-259,458-246,812-224,193-207,686-191,993-169,031-151,311-129,856-111,449-97,665-82,030-68,648-58,393-46,807-33,84000-10,822
   Capital Surplus 
0
0
0
0
0
0
0
0
278,728
278,728
278,842
278,842
278,842
278,842
278,842
278,842
278,842
319,882
322,663
322,663
361,981
362,020
362,440
362,440362,020361,981322,663322,663319,882278,842278,842278,842278,842278,842278,842278,842278,728278,72800000000
   Treasury Stock00000000000000000000000
   Other Stockholders Equity 
62,458
0
0
98,031
279,032
278,651
278,728
278,728
278,728
278,728
278,842
278,842
278,842
278,842
278,842
278,842
278,842
320,185
322,663
322,663
362,265
362,020
362,440
362,440362,020362,265322,663322,663320,185278,842278,842278,842278,842278,842278,842278,842278,728278,728278,728278,728278,651279,03298,0310062,458



Balance Sheet

Currency in SEK. All numbers in thousands.




Cash Flow

Currency in SEK. All numbers in thousands.




Income Statement

Currency in SEK. All numbers in thousands.


Latest Income Statement (annual, 2022-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-56,569
Operating Income-56,442-56,569
 
Operating Expense (+$)
Research Development46,183
Selling General Administrative10,168
Selling And Marketing Expenses0
Operating Expense56,56956,351
 
Net Interest Income (+$)
Interest Income207
Interest Expense-4
Other Finance Cost-0
Net Interest Income203
 
Pretax Income (+$)
Operating Income-56,442
Net Interest Income203
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-56,239-56,645
EBIT - interestExpense = -56,446
-56,239
-56,032
Interest Expense4
Earnings Before Interest and Taxes (EBIT)-56,442-56,235
Earnings Before Interest and Taxes (EBITDA)-55,665
 
After tax Income (+$)
Income Before Tax-56,239
Tax Provision-0
Net Income From Continuing Ops-56,239-56,239
Net Income-56,036
Net Income Applicable To Common Shares-56,239
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses56,569
Total Other Income/Expenses Net203-203
 

Technical Analysis of AlzeCure Pharma
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of AlzeCure Pharma. The general trend of AlzeCure Pharma is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine AlzeCure Pharma's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of AlzeCure Pharma.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 4.23 < 4.39 < 4.52.

The bearish price targets are: 3.28 > 3.24 > 3.13.

Tweet this
AlzeCure Pharma Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of AlzeCure Pharma. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

AlzeCure Pharma Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of AlzeCure Pharma.

AlzeCure Pharma Daily Moving Average Convergence/Divergence (MACD) ChartAlzeCure Pharma Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of AlzeCure Pharma. The current adx is .

AlzeCure Pharma Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of AlzeCure Pharma.

AlzeCure Pharma Daily Parabolic SAR Chart
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of AlzeCure Pharma.

AlzeCure Pharma Daily Relative Strength Index (RSI) ChartAlzeCure Pharma Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of AlzeCure Pharma.

AlzeCure Pharma Daily Stochastic Oscillator ChartAlzeCure Pharma Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of AlzeCure Pharma.

AlzeCure Pharma Daily Commodity Channel Index (CCI) ChartAlzeCure Pharma Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of AlzeCure Pharma.

AlzeCure Pharma Daily Chande Momentum Oscillator (CMO) ChartAlzeCure Pharma Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of AlzeCure Pharma.

AlzeCure Pharma Daily Williams %R ChartAlzeCure Pharma Daily Williams %R Chart
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of AlzeCure Pharma.

AlzeCure Pharma Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of AlzeCure Pharma.

AlzeCure Pharma Daily Average True Range (ATR) ChartAlzeCure Pharma Daily Average True Range (ATR) Chart
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of AlzeCure Pharma.

AlzeCure Pharma Daily On-Balance Volume (OBV) ChartAlzeCure Pharma Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of AlzeCure Pharma.

AlzeCure Pharma Daily Money Flow Index (MFI) ChartAlzeCure Pharma Daily Money Flow Index (MFI) Chart
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for AlzeCure Pharma.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-05-11STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-05-15STOCH SHORT EXITThe %K line crosses above the %D line.
2023-05-17CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-05-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-05-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-05-23CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-05-24SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-05-26MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-05-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-05-30STOCH SHORT EXITThe %K line crosses above the %D line.
2023-05-31WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-06-01STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-06-05STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-06-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-06-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-06-09RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-06-12WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-06-13MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-06-14RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-06-15STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-06-19STOCH LONG EXITThe %K line crosses below the %D line.
2023-06-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-06-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-06-26CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-06-27CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-06-28STOCH SHORT EXITThe %K line crosses above the %D line.
2023-06-30STOCH LONG EXITThe %K line crosses below the %D line.
2023-07-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-07-06CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-07-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-07-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-07-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-07-17WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-07-18STOCH SHORT EXITThe %K line crosses above the %D line.
2023-07-19STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-07-21CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-07-25STOCH SHORT EXITThe %K line crosses above the %D line.
2023-07-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-07-31STOCH LONG EXITThe %K line crosses below the %D line.
2023-08-02STOCH SHORT EXITThe %K line crosses above the %D line.
2023-08-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-08-07CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-08-08STOCH SHORT EXITThe %K line crosses above the %D line.
2023-08-11STOCH LONG EXITThe %K line crosses below the %D line.
2023-08-15STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-08-16STOCH SHORT EXITThe %K line crosses above the %D line.
2023-08-17MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-08-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-08-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-08-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-08-23STOCH LONG EXITThe %K line crosses below the %D line.
2023-08-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-08-25CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-08-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-08-29CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-08-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-08-31WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-09-05STOCH SHORT EXITThe %K line crosses above the %D line.
2023-09-06STOCH LONG EXITThe %K line crosses below the %D line.
2023-09-08STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-09-12STOCH LONG EXITThe %K line crosses below the %D line.
2023-09-14STOCH SHORT EXITThe %K line crosses above the %D line.
2023-09-15RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-09-18SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-09-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-09-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-09-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-09-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-09-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-09-28STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

AlzeCure Pharma Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of AlzeCure Pharma based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose3.900
Total0/1 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of AlzeCure Pharma with someone you think should read this too:
  • Are you bullish or bearish on AlzeCure Pharma? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about AlzeCure Pharma? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about AlzeCure Pharma

I send you an email if I find something interesting about AlzeCure Pharma.


Comments

How you think about this?

Leave a comment
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

Stay informed about AlzeCure Pharma.

Receive notifications about AlzeCure Pharma in your mailbox!